Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sichuan Zitonggong Pharmaceutical Co EBITDA Margin %?
Sichuan Zitonggong Pharmaceutical CoBJSE:920566 83 EBITDA Margin % is 13.27% as of Jun. 2026, which is 57% below its 10-year median of 30.89. GuruFocus rates BJSE:920566 with a GF Score™ of 83/100 and a GF Value™ of ¥10.55 (Fairly Valued). The stock has 1 warning sign investors should review. Among 958 Drug Manufacturers companies, Sichuan Zitonggong Pharmaceutical Co ranks better than 75.26% on this metric.
Sichuan Zitonggong Pharmaceutical Co (BJSE:920566) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sichuan Zitonggong Pharmaceutical Co EBITDA Margin % Related Terms
Sichuan Zitonggong Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Zitonggong Pharmaceutical Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Zitonggong Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Zitonggong Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sichuan Zitonggong Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sichuan Zitonggong Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Zitonggong Pharmaceutical Co (BJSE:920566) has a EBITDA Margin % of 13.27% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sichuan Zitonggong Pharmaceutical Co and its competitors. This is 57% below median its historical median of 30.89. Over the past decade, Sichuan Zitonggong Pharmaceutical Co's EBITDA Margin % has ranged from 17.85 to 34.80. According to the industry distribution chart, Sichuan Zitonggong Pharmaceutical Co ranks #237 out of 958 companies in the Drug Manufacturers industry, placing it in the top 24.7%.
Is Sichuan Zitonggong Pharmaceutical Co's EBITDA Margin % too high?
Sichuan Zitonggong Pharmaceutical Co's current EBITDA Margin % of 13.27% is 57% below median its 10-year median of 30.89. Over the past 10 years, this metric has ranged from a low of 17.85 to a high of 34.80. The Drug Manufacturers industry median EBITDA Margin % is 12.01. Sichuan Zitonggong Pharmaceutical Co's value of 13.27% is 10.5% above this industry median. Based on the distribution chart, Sichuan Zitonggong Pharmaceutical Co ranks #237 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sichuan Zitonggong Pharmaceutical Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Zitonggong Pharmaceutical Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sichuan Zitonggong Pharmaceutical Co ranks #237 out of 958 companies for EBITDA Margin %. This places Sichuan Zitonggong Pharmaceutical Co in the top 25% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.01. Sichuan Zitonggong Pharmaceutical Co's value of 13.27% is 10.5% above this benchmark. Historically, Sichuan Zitonggong Pharmaceutical Co's own EBITDA Margin % has ranged from 17.85 to 34.80 over the past decade. While the company's 10-year median is 30.89 vs. the industry median of 12.01, Sichuan Zitonggong Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.01, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Zitonggong Pharmaceutical Co's current EBITDA Margin % of 13.27% is 10.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sichuan Zitonggong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Zitonggong Pharmaceutical Co's current EBITDA Margin % is 13.27%, which is 57% below median its own 10-year median of 30.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Zitonggong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Zitonggong Pharmaceutical Co (BJSE:920566) is currently considered Fairly Valued. The stock's GF Value™ is ¥10.55, compared to a current price of ¥9.79 — trading 7.2% below its estimated fair value. The current EBITDA Margin % is 13.27%, which is 57% below median its 10-year median of 30.89 and 10.5% above the Drug Manufacturers industry median of 12.01. Sichuan Zitonggong Pharmaceutical Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sichuan Zitonggong Pharmaceutical Co (BJSE:920566), the current EBITDA Margin % is 13.27% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Zitonggong Pharmaceutical Co (BJSE:920566) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Zitonggong Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥9.79 is trading 7.2% below its estimated GF Value™ of ¥10.55.
GuruFocus considers Sichuan Zitonggong Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920566:
EBITDA Margin %: 13.27% (57% below median its 10-year median of 30.89)
GF Value™: ¥10.55 vs. price of ¥9.79 (7.2% below fair value)
Industry Position: 10.5% above the Drug Manufacturers median (#237 of 958)
No single metric tells the full story. See the BJSE:920566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Zitonggong Pharmaceutical Co Ltd is a high-tech enterprise focusing on the R&D, production, and marketing of tablets, hard capsules, liniments, powders, and ointments. It has developed a number of drug varieties, such as Citicoline Sodium Tablets and Rizatriptan Benzoate Capsules.
83GF Score
Get the complete analysis for BJSE:920566
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920566 has been successfully added to your 
